18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00511732
Recruitment Status : Completed
First Posted : August 6, 2007
Last Update Posted : April 30, 2012
Information provided by (Responsible Party):
Mannkind Corporation

Brief Summary:
Designed to evaluate dose response of force-titrated prandial administration of TI as compared to placebo (TP) in subjects with Type 2 diabetes who were suboptimally controlled

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Drug: Technosphere Insulin Drug: Technosphere Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 227 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Controlled, Stepwise Titration Study to Evaluate Dose Response to Prandial Administration of Inhaled Technosphere/Insulin or Technosphere in Patients With Type 2 Diabetes Mellitus Who Are Sub-optimally Treated
Study Start Date : June 2004
Actual Primary Completion Date : August 2005
Actual Study Completion Date : August 2007

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Technosphere Insulin Drug: Technosphere Insulin
Technosphere Insulin Inhalation Powder

Placebo Comparator: Technosphere Inhalation Powder Drug: Technosphere Placebo
Technosphere Inhalation Powder

Primary Outcome Measures :
  1. HbA1c change from baseline (week 6) to end of treatment (week 17) [ Time Frame: measured from week 6 (baseline) to week 17 ]
  2. Area under the plasma glucose concentration versus time (AUCglucose) compared to week 6 (baseline. [ Time Frame: at weeks 4, 6, 11 and 17 ]
    Timepoints: 0 minutes (before meal) and at 15, 30, 60, 90, 120, 180, 240, and 300 minutes after TI administration

  3. Area under the plasma glucose concentration versus time (AUCglucose) compared to week 6 (baseline) [ Time Frame: at weeks 4, 6, 11 and 17 ]
    Timepoints: 0 minutes (before meal) and at 15, 30, 60, 90, 120, 180, 240, and 300 minutes after Technosphere Placebo administration

Secondary Outcome Measures :
  1. Fasting blood glucose concentration compared to week 6 (baseline) [ Time Frame: at weeks 4, 6, 11 and 17 ]
  2. Safety variables included adverse events (AEs), clinical laboratory tests, vital signs and physical examinations [ Time Frame: 18 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and females patients from 18 to <80 years of age
  • Clinical diagnosis of type 2 diabetes mellitus
  • Duration of diabetes of >3 years and <20 years
  • Glycemic control at upper end of acceptable level or sub-optimal in control (HbA1c between 7.0% and 12?0%)
  • Confirmation of diagnosis of diabetes such as a history of 2 hour postprandial blood glucose >11.1 mmol/L (200 mg/dL) or following a glucose tolerance test
  • A minimum of 2 months of treatment with a stable dose of one or more of the following anti-hyperglycemic agents: sulphonylureas, alpha glucosidase inhibitors, metformin, meglitinides, thiazolidinediones and/or Lantus basal insulin therapy
  • FBG:>6 mmol/L (108 mg/dL)
  • C-peptide: >0.5 nmol/L
  • BMI <38 kg/m2
  • Baseline DLco, FVC, FEV1 >75% of predicted normal
  • Subjects who, in the opinion of the Investigator, will be able to complete this study
  • Written informed consent

Exclusion Criteria:

  • Severe complications of diabetes including history of: blindness from or grade III or IV diabetic retinopathy, renal failure requiring dialysis or transplantation, amputation of limbs or digits related to diabetic vasculopathy or foot ulcers
  • Treatment with another investigational drug within 3 months prior to study entry and for the duration of the study
  • History of drug or alcohol dependency
  • Significant hepatic disease (as evidenced by ALT or AST >3 times the normal upper reference range or bilirubin >1.5 times the normal upper reference range)
  • Significant renal disease (as evidenced by creatinine >1.5 mg/dL for males or >1.3 mg/dL for females) or proteinuria >1,000 mg/24 hours
  • History of chronic obstructive pulmonary disease, or history of other known chronic pulmonary diseases, such as reactive airway disease, chronic bronchitis, emphysema, or asthma
  • Heart disease graded as class III or class IV according to New York Heart Association criteria
  • Prior treatment with , or participation in a clinical study involving an inhaled insulin product
  • Smokers
  • Current use of preprandial or prandially administered fast-acting or rapid acting insulin or insulin analogs
  • Previous participation in a TI or TP clinical trial
  • Allergy to insulin or to any drugs to be used as part of the clinical trial
  • History of malignancy within 5 years of study entry (other than basal cell carcinoma)
  • Anemia (hemoglobin level less than 11 g/dL for females or 12 g/dL for males at study entry)
  • Diagnosis of Acquired Immunodeficiency Syndrome (AIDS) and Aids Related Complex A major psychiatric disorder that will preclude satisfactory participation in this study
  • Subjects who have had a myocardial infarction or stroke within the preceding 6 months
  • Prior diagnosis of systemic autoimmune or collagen vascular disease requiring previous or current treatment with systemic corticosteroids, cytotoxic drugs, or penicillamine
  • History of severe or multiple allergies
  • Progressive fatal disease
  • Recent loss (within the past 2 months) of >5% of body weight
  • Evidence of "moderate" or greater ketones in urine or history of ketoacidosis
  • Use of medications known to modify glucose metabolism or the ability to recover from hypoglycemia such as oral, parenteral and inhaled steroids, or greater than 25 mg hydrochlorothiazide daily
  • Women who are pregnant or lactating
  • Women of childbearing potential practicing inadequate birth control (adequate birth control is defined as using oral contraceptives, condoms or diaphragms with spermicide, intrauterine devices, or surgical sterilization).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00511732

Sponsors and Collaborators
Mannkind Corporation
Study Director: Anders Boss Mannkind Corporation

Responsible Party: Mannkind Corporation Identifier: NCT00511732     History of Changes
Other Study ID Numbers: MKC-TI-005
First Posted: August 6, 2007    Key Record Dates
Last Update Posted: April 30, 2012
Last Verified: April 2012

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Hypoglycemic Agents
Physiological Effects of Drugs